Open innovation: the new face of pharmaceutical research and development
Authors:
- Kenneth A GetzKGKenneth A Getz
- Kenneth I KaitinKKKenneth I Kaitin
- 1 September 2012
- journal article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 5 (5) , 481-483
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Variability in Protocol Design Complexity by Phase and Therapeutic AreaDrug Information Journal, 2011
- The productivity crisis in pharmaceutical R&DNature Reviews Drug Discovery, 2011
- Measuring the Incidence, Causes, and Repercussions of Protocol AmendmentsDrug Information Journal, 2011
- Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009Clinical Pharmacology & Therapeutics, 2010
- Trends in Risks Associated With New Drug Development: Success Rates for Investigational DrugsClinical Pharmacology & Therapeutics, 2010
- Deconstructing the Drug Development Process: The New Face of InnovationClinical Pharmacology & Therapeutics, 2010
- Is open innovation the way forward for big pharma?Nature Reviews Drug Discovery, 2010
- Lessons from 60 years of pharmaceutical innovationNature Reviews Drug Discovery, 2009
- Drug Development Portfolio and Spending Practices after Mergers and AcquisitionsDrug Information Journal, 2009
- The cost of biopharmaceutical R&D: is biotech different?Managerial and Decision Economics, 2007